- Home
- GTY vs COLL Comparison
GTY vs COLL Comparison
Compare GTY & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GTY | COLL |
|---|---|---|
| Founded | 1955 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | GTY | COLL |
|---|---|---|
| Price | $28.77 | $49.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $31.80 | ★ $47.50 |
| AVG Volume (30 Days) | 380.8K | ★ 515.8K |
| Earning Date | 10-22-2025 | 11-06-2025 |
| Dividend Yield | ★ 6.80% | N/A |
| EPS Growth | ★ 10.25 | N/A |
| EPS | 1.28 | ★ 1.63 |
| Revenue | $214,194,000.00 | ★ $757,067,000.00 |
| Revenue This Year | $6.23 | $26.35 |
| Revenue Next Year | $8.82 | $3.67 |
| P/E Ratio | ★ $22.33 | $29.92 |
| Revenue Growth | 8.17 | ★ 26.34 |
| 52 Week Low | $25.39 | $23.23 |
| 52 Week High | $32.60 | $49.16 |
Technical Indicators
Market Signals| Indicator | GTY | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 61.92 | 71.79 |
| Support Level | $28.31 | $47.86 |
| Resistance Level | $28.79 | $49.16 |
| Average True Range (ATR) | 0.41 | 1.33 |
| MACD | 0.01 | -0.15 |
| Stochastic Oscillator | 90.48 | 92.01 |
Price Performance
Historical ComparisonAbout GTY Getty Realty Corporation
Getty Realty Corp is the real estate investment trust in the U.S. specializing in the acquisition, financing, and development of convenience, automotive, and other single tenant retail real estate. The company's portfolio includes convenience stores, car washes, automotive service centers (gasoline and repair, oil and maintenance, tire and battery, collision), automotive parts retailers, and certain other freestanding retail properties, including drive-thru quick service restaurants. It generates majority of the revenue in the form of rental income.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.